IL1B and neoplasm: We provide evidence that co-treatment of myeloid tumour cells with TLR ligands in conjunction with proteasome inhibition can affect tumour growth by (1) modulation of IL-1β synthesis and maturation and (2) increasing caspase-dependent and caspase-independent modes of cell death.